Intellia Therapeutics Scientific Co-Founder Shares Nobel Prize in Chemistry with Collaborator
On October 07, 2020 Jennifer Doudna, Ph.D., one of Intellia Therapeutics (NTLA) scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr. Doudna shared the award with her research collaborator, Dr. Emmanuelle Charpentier, one of . . .